Should Xpert® MTB/RIF be rolled out in low-income countries? Reply

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 5, 2012, Pages 703-704

  Trebucq A ^a   Harries, A D ^a   Rieder, H L ^a  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN;

DIAGNOSTIC ACCURACY; DISEASE TRANSMISSION; HUMAN; LETTER; LOW INCOME COUNTRY; LUNG TUBERCULOSIS; MOLECULAR DIAGNOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; SOCIETY; SOCIOECONOMICS; SPUTUM CYTODIAGNOSIS;

EID: 84859732864     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0034-2     Document Type: Letter

References (4)

1. Trébucq A, Enarson D A, Chiang C-Y, et al. Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? Int J Tuberc Lung Dis 2011; 15: 1567-1571.
2. Zumla A. The Global Fund Round 11 cancellation fiasco: turning disaster into opportunity? [Editorial] Int J Tuberc Lung Dis 2012; 16: 285-286.
3. Espinal M A, Kim S J, Suarez P G, et al. Standard short-course chemotherapy for drug-resistant tuberculosis. Treatment outcomes in 6 countries. JAMA 2000; 283: 2537-2545. (Pubitemid 30324196)
4. World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test. Technical and operational 'How-to'. Practical considerations. WHO/HTM/TB/2011.2. Geneva, Switzerland: WHO, 2011.